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Background andAims: Malignant mesothelioma is an aggressive, therapy-resistant tumor.
Mesothelioma cells may assume an epithelioid or a sarcomatoid phenotype, and presence
of sarcomatoid cells predicts poor prognosis. In this study, we investigated differentiation
of mesothelioma cells in a xenograft model, where mesothelioma cells of both phenotypes
were induced to form tumors in severe combined immunodeficiency mice.
Methods: Xenografts were established and thoroughly characterized using a compre-
hensive immunohistochemical panel, array comparative genomic hybridization (aCGH) of
chromosome 3, fluorescent in situ hybridization, and electron microscopy.
Results: Epithelioid and sarcomatoid cells gave rise to xenografts of similar epithelioid
morphology. While sarcomatoid-derived xenografts had higher growth rates, the morphol-
ogy and expression of differentiation-related markers was similar between xenografts
derived from both phenotypes. aCGH showed a convergent genotype for both xenografts,
resembling the original aggressive sarcomatoid cell sub-line.
Conclusion: Human mesothelioma xenografts from sarcomatoid and epithelioid pheno-
types converged to a similar differentiation state, and genetic analyses suggested that
clonal selection in the mouse microenvironment was a major contributing factor. This thor-
oughly characterized animal model can be used for further studies of molecular events
underlying tumor cell differentiation.
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BACKGROUND
Malignant mesothelioma is a tumor that arises from mesothe-
lial cells lining the serosal cavities. Mesothelial cells display an
intermediate epithelial-mesenchymal phenotype, and characteris-
tically co-express both epithelial and mesenchymal markers, such
as cytokeratins and vimentin (1). Mesothelial progenitor cells are
able to switch between different cell phenotypes depending on
the local environment, and they can differentiate to epithelioid or
mesenchymal phenotypes during tissue homeostasis in vivo (2–6).
This plasticity of mesothelial cells and the potential to differenti-
ate between these two phenotypes is retained also in malignant
mesothelioma cells in vitro (7–9). This differentiation into sta-
ble epithelioid or fibroblast-like/sarcomatoid phenotypes can be
induced in vitro by serum growth factors (10). Thus,mesothelioma
cells provide a useful model for identifying critical mechanisms
involved in the regulation of tumor cell differentiation.
Histological phenotype is the most important prognostic
marker for malignant mesothelioma; predominance of a sarcoma-
toid component indicates worse prognosis and therapy resistance
(11–13). Mesothelioma cells of the two different phenotypes have
distinct gene expression signatures (14–17). We have previously
shown that sarcomatoid mesothelioma cells overexpress growth
factor receptors and associated binding proteins, whereas epithe-
lioid mesothelioma cells overexpress tumor promoting factors
involved in differentiation, metabolism, and proteasome activa-
tion (14). Overall, the expression profile of the epithelioid cell-
line reflects a more differentiated tumor. Sarcomatoid mesothe-
lioma cells, however, have a profile associated with growth factors
and genes which may contribute to the particularly unfavorable
prognosis of sarcomatoid tumors.
Epithelioid and sarcomatoid phenotypes also differ in drug
sensitivity profiles (18, 19). A deeper understanding of trans-
differentiation between epithelioid and sarcomatoid phenotypes is
relevant for the development of therapeutics, and should be taken
into consideration when designing in vitro studies and establish-
ing animal models. Mouse models of malignant mesothelioma
have been previously described; however, only a few studied the
differentiation state of the xenografts (20–22).
In this study, we describe the establishment of a mouse
xenograft model for malignant mesothelioma, where cells of
epithelioid and sarcomatoid phenotypes were injected subcu-
taneously and concurrently into Severe Combined Immunod-
eficiency (SCID) mice. We report extensive characterization of
the resulting xenografts using immunohistochemistry, electron
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microscopy, and chromosome 3 array comparative genomic
hybridization (aCGH); with particular regard to the differentia-
tion state and genotype of the original cells and their correspond-
ing xenografts. Genetic analyses were performed on chromosome
3, which is one of the most rearranged chromosomes in solid
tumors (23). Several earlier studies have highlighted rearrange-
ments on chromosome 3 in malignant mesothelioma (24–27), and
we have previously shown that the frequency of rearrangements
at specific break-points on chromosome 3 correlates to the degree
of genomic instability in cancer cells (28, 29).
MATERIALS AND METHODS
CELLS AND CULTURE CONDITIONS
This study was performed using a well-established model system
for malignant mesothelioma differentiation, consisting of STAV-
AB and STAV-FCS sub-lines (Figure 1A). Cells were originally
derived from a single tumor, and subsequently induced to differ-
entiate into stable epithelioid (STAV-AB) and sarcomatoid (STAV-
FCS) phenotypes, respectively, by altering the serum composition
(10). STAV-AB cells were grown in Gibco RPMI 1640 medium
(Invitrogen) and 10% human AB serum, whereas STAV-FCS cells
were grown in the same medium and 10% fetal calf serum. All
cells were grown in 75 cm2 tissue culture flasks (Sarstedt, New-
ton, MA, USA) at 37°C in 5% CO2. Both cell sub-lines have been
thoroughly characterized by genome-wide screening with regard
to their differentiation state and their molecular signature (14, 30).
ESTABLISHMENT OF XENOGRAFTS IN SCID MICE
For establishment of the xenograft model epithelioid (STAV-AB)
and sarcomatoid (STAV-FCS) mesothelioma cells with distinct
phenotypes (Figure 1A) were inoculated into SCID mice. One
million cells in 0.2 ml Iscove’s modified Dulbecco’s medium were
inoculated subcutaneously or intraperitoneally into 6-week old
mice. Three independent experiments were performed with a total
number of 19 mice. In the first two experiments, cells were injected
subcutaneously and intraperitoneally and the animals were mon-
itored for 8 weeks with no signs of tumor formation. In the third
experiment, mice were inoculated subcutaneously with STAV-AB
in one flank and STAV-FCS cells in the other flank. When the
xenografts reached the maximal ethically tolerable tumor burden
the animals were sacrificed and the tumors were excised and after
homogenization serially passaged to the next generation of SCID
mice. The xenografts used for subsequent analyses were randomly
selected from the second generations of tumors.
CHROMOSOME 3 ARRAY COMPARATIVE GENOMIC HYBRIDIZATION
A set of 174 commercially available BAC/PAC clones were selected
for a chromosome 3 specific array from BACPAC Resources Cen-
ter, Children’s Hospital Oakland, Oakland, USA1; all clones were
mapped by fluorescence in situ hybridization (FISH), they were at
least partially sequenced, their localization was approved using the
UCSC database2, they were chromosome 3 specific, non-chimeric,
and covered the whole chromosome with a resolution of ∼1 Mb.
Total genomic DNA was isolated using the GenElute mammalian
1http://bacpac.chori.org/
2http://genome.ucsc.edu/
FIGURE 1 | Mesothelioma cells and xenografts. (A) Phase-contrast
micrographs showing epithelioid cobblestone-like morphology in STAV-AB
cells, and elongated fibroblast-like morphology in STAV-FCS cells. Scale
bars are 200µm. (B,C) Tumor volume after inoculation of mesothelioma
cells into SCID mice displaying epithelioid (STAV-AB) or sarcomatoid
(STAV-FCS) phenotypes, respectively. After establishment, tumors were
serially passed through a second set of mice.
genomic DNA miniprep kit (Sigma-Aldrich, Germany). DNA
labeling, hybridization and post-hybridization processing, scan-
ning, and image analysis were performed as previously described
(28). The average and coefficient of variation of fluorescence ratios
for each measurement point were calculated. Data points display-
ing a coefficient of variation >5% between at least two of the replica
spots were excluded from further analysis. The average of fluores-
cence ratios from autosomal controls was used in the normaliza-
tion of data in each hybridization experiment. All aCGH data have
been deposited in NCBI’s Gene Expression Omnibus (31), and are
accessible through GEO accession number GSE480193.
IMMUNOHISTOCHEMISTRY AND HISTOCHEMISTRY
Based on our previous molecular characterization (14, 17, 30),
a panel of antibodies was selected to stain the xenografts.
3http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE48019
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Calretinin (DAKO), was included as a marker for mesothe-
lial lineage. Epithelioid differentiation was investigated using
MNF-116 (DAKO), epithelial membrane antigen (EMA) (DAKO),
Cam5.2, high molecular weight cytokeratins (CK-HMW) (Novo-
castra Laboratories), cytokeratin 7 (Novocastra Laboratories),
cytokeratin 8 (Novocastra Laboratories), E-cadherin (Novo-
castra Laboratories), and syndecan-1 (DAKO). Syndecan-
2 (Santa Cruz Biotechnology) and vimentin (DAKO) were
used as markers for mesenchymal differentiation. We also
included the proliferation marker MIB-1 (DAKO), annexin-
II, Heat Shock Protein-47 (HSP47), integrin αVβ5 (Chemi-
con), and thioredoxin reductase 1 (TrxR1) (Upstate), which
have been shown to be differentially expressed between the
two mesothelioma phenotypes (17, 18, 32). Isotype IgG con-
trols were used to estimate the non-specific binding of tar-
get primary antibodies to cell surface antigens. Vascular den-
sity in xenografts was demonstrated by silver staining of
reticulin fibers according to Gordon and Sweets (33, 34).
Vascular density in xenografts was measured by point-counting,
comparing different areas using two-sided Student’s t -tests,
taking α= 0.05.
Immunostainings were performed on cytospin preparations
from cell lines, and on formalin-fixed paraffin-embedded sections
from xenografts (n= 1 per cell sub-line). After deparaffiniza-
tion and hydration, tissue sections were microwave-treated for
antigen retrieval in 10 mM sodium citrate buffer, pH 6.0 for
15 min. Staining was performed following the microwave strep-
tavidin immunoperoxidase (MSIP) protocol on a DakoCy-
tomation TechMate™ instrument (DAKO, Copenhagen, Den-
mark). Non-specific binding was blocked by 0.5% BSA-TBST
(ChemMate™ Detection Kit, DAKO) and endogenous perox-
idase activity was abolished by the ChemMate™ Peroxidase-
Blocking Solution (S 2023, DAKO). Reaction products were
visualized with the streptavidin-biotin-peroxidase method using
diaminobenzidine as substrate-chromogen and with hematoxylin
as counterstain. Immunohistochemical staining intensities were
FIGURE 2 | Histological analysis of xenografts and immunohistochemical
staining for MIB-1, Integrin α5, and epithelial and mesenchymal markers.
Hematoxylin/eosin staining revealed a similar epithelioid phenotype in
xenografts originating from both STAV-AB and STAV-FCS cell sub-lines. MIB-1
staining indicated proliferative activity in both xenografts, however, less
vascularized areas of STAV-FCS xenografts (left sub-panel) showed lower
labeling index than more vascularized peripheral areas (right sub-panel).
Expression of vimentin, a mesenchymal differentiation marker, was strong in
xenografts from both cell sub-lines, as was expression of the integrin α5
subunit. Similarly, MNF-116, an epithelial differentiation marker, was strongly
expressed in xenografts from both cell sub-lines. TrxR1 showed a difference in
staining pattern between xenografts of the two cell sub-lines, where
STAV-FCS-derived xenografts showed a stronger nuclear immunoreactivity.
STAV-AB-derived xenografts also, however, stained positively for TrxR1.
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FIGURE 3 | Immunohistochemical staining of xenografts for markers of epithelial differentiation. Xenografts from both cell sub-lines stained uniformly
and similarly positive for EMA, E-cadherin, CK-HMW, CK7, and CAM 5.2, and negative for CK8. These proteins are markers for epithelioid differentiation.
evaluated semi-quantitatively and referred to as weak (+), mod-
erate (++), or strong (+++), respectively, by two experienced
pathologists (Katalin Dobra and Anders Hjerpe). Discrepant
cases were re-evaluated and discussed to reach consensus. Ves-
sels were identified in silver stained slides, for morphometrical
determination of microvessel density and vessel volume density,
respectively.
FLUORESCENT IN SITU HYBRIDIZATION
Chromosomal ploidy patterns were obtained by FISH analysis,
using the UroVysion® kit (Abbot). This probe set is used in
clinical practice for detecting p16 and the centromeres of chromo-
somes 3, 7, and 17 (35). Hybridization reactions were performed
on cytospin preparations of cultured cells and on formalin-fixed
paraffin-embedded sections of xenograft tissue. Four additional
chromosome 3 PAC/BAC probes (Rp11-266L17/RP11-89H10 and
RP11-356G4/RP11-13k6) were used to analyse the STAV-AB and
STAV-FCS cell lines.
TRANSMISSION ELECTRON MICROSCOPY
Xenografts were dissected and small pieces were fixed in
2% glutaraldehyde+ 0.5% paraformaldehyde in 0.1 M sodium
cacodylate buffer containing 0.1 M sucrose and 3 mM CaCl2, pH
7.4, at room temperature for 30 min followed by 24 h at 4°C. Speci-
mens were then rinsed in 0.1 M phosphate buffer, pH 7.4, postfixed
in 2% osmium tetroxide 0.1 M phosphate buffer, pH 7.4, at 4°C
for 2 h, dehydrated in ethanol followed by acetone, and embedded
in LX-112 (Ladd, Burlington, VT, USA). Semithin sections were
cut and stained with toluidine blue and used for light microscopic
analysis. Ultrathin sections (∼40–50 nm) were cut and contrasted
with uranyl acetate followed by lead citrate and examined in a Leo
906 transmission electron microscope at 80 kV (Leo, Oberkochen,
Germany).
ETHICAL APPROVAL
This study was approved by the regional Animal Experiment Ethics
Review Committee of Northern Stockholm (N19/05).
RESULTS
GROWTH CHARACTERISTICS OF XENOGRAFTS
Following inoculation of STAV-AB and STAV-FCS cells into SCID
mice, STAV-FCS xenografts had a considerably higher growth rate
than those derived from STAV-AB cells. Tumor formation of the
STAV-FCS cells could be detected by palpation after 12 weeks. For
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FIGURE 4 | Immunohistochemical staining of xenografts for mesothelial and mesenchymal differentiation markers. Xenografts from both cell sub-lines
stained uniformly and similarly positive for Syndecan-1, Syndecan-2, Calretinin, Annexin-II, HSP47, and SM actin.
STAV-AB, 14 weeks were required before subcutaneous tumors
could be detected. Experiments with shorter incubation periods
showed no tumor formation.
Tumor take after 15 weeks was 3/10; two of five mice inoc-
ulated with STAV-FCS and one of five with STAV-AB cells. In
the second generation, tumor take was 3/3 for STAV-FCS and
2/3 for STAV-AB (Figures 1B,C). At serial passage, STAV-FCS
cells gave rise to rapidly growing tumors that were detected
already after 1 week, whereas STAV-AB xenografts were palpa-
ble only after 4 and 4.5 weeks after inoculation and grew slower
(Figures 1B,C). Xenografts from STAV-FCS cells grew faster than
STAV-AB, enabling a third passage to be performed with the
STAV-FCS cells.
XENOGRAFTS OF BOTH CELL SUB-LINES CONVERGED TO A SIMILAR
EPITHELIOID-LIKE MORPHOLOGY
Light microscopy of xenografts showed a similar, epithelioid-like
morphology regardless of the original phenotype of the inocu-
lated cell sub-lines (Figure 2). Remarkably, xenografts derived
from both STAV-AB and STAV-FCS cells showed similar staining
patterns for most of the tested antigens, comprising a broad range
of mesothelial, epithelial, and mesenchymal markers (Figures 2–4;
Table 1). Integrin αVβ5 stained positively in xenografts from both
cell sub-lines, with a modest accentuation at the tumor invasion
front of the STAV-AB-derived xenografts (Figure 2).
MIB-1 staining indicated that both xenografts were highly
proliferative. Despite that STAV-FCS-cell-derived xenografts grew
faster and reached the maximal size earlier in SCID mice, this
tissue showed areas with reduced MIB-1 labeling index. These
areas of less proliferation were mainly seen in the central parts
of xenografts, corresponding to decreased vascularization, and
areas of necrosis. Both microvessel density and vessel volume
density, as demonstrated in the reticulin stained samples, were
significantly greater close to the infiltration front, while only
a few vessels were seen deeper than 1.2 mm in the tumor tis-
sue (Figure 5; Tables 3 and 4). At distance from the tumor
front the sarcomatoid cell xenografts contained significantly less
vessels compared to the corresponding areas in the epithelioid
cell xenografts, and the difference between surface and deeper
layers was most apparent in the sarcomatoid cell STAV-FCS
preparation.
TrxR1, which in culture is more expressed in the STAV-
AB cell line, showed greater reactivity in the STAV-FCS-derived
xenografts, and this reactivity was mainly nuclear (Figure 2;
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Darai-Ramqvist et al. Phenotypic changes in mesothelioma xenografts
Table 1 | Immunohistochemical analyses of xenografts.
STAV-AB
xenograft
STAV-FCS
xenograft
Localization
MESOTHELIAL AND EPITHELIAL MARKERS
Calretinin ++ ++ Cytoplasm and nucleus
EMA + +(+) Cell membrane
E-cadherin + (Focal) + Cell membrane
CK-HMW ++ ++ Cytoplasm
Cytokeratin 7 + ++ Cytoplasm
Cytokeratin 8 − − Cytoplasm
Cam 5.2 +++ ++ Cell membrane and
cytoplasm
Syndecan-1 + + Cell membrane
MNF-116 +++ +++ Cell membrane and
cytoplasm
DIFFERENTIATION-RELATED MARKERS
TrxR1 ++ +++ Cytoplasm and nucleus
Integrin α5 + + Cytoplasm
HSP-47 +++ +++ Cell membrane and
cytoplasm
Annexin-II ++ ++ Cell membrane
MESENCHYMAL MARKERS
Vimentin ++ ++ Cytoplasm
SM actin +(+) + Cytoplasm
Syndecan-2 ++ ++ Cytoplasm
PROLIFERATION MARKER
Mib-1 >80% 40% Nucleus
Table 1). No immunoreactivity was seen when using goat serum
and isotype IgG controls (data not shown).
FISH ANALYSES DEMONSTRATED HETEROGENEOUS CELL
POPULATIONS
Cytogenetic analysis by FISH proved that both the original cell
lines and the derived xenografts were heterogeneous. FISH analysis
by the UroVysion probe set and four additional PAC/BAC probes
located on chromosome 3 showed maintained heterogeneous sub-
populations at around 10% for STAV-AB and around 20% for the
FCS cell line. In the xenografts, the UroVysion probe set indi-
cated that 20% of the cells in STAV-AB derived xenografts and
around 30% of the cells in STAV-FCS derived ones, represented
non-dominant clones.
ELECTRON MICROSCOPY DEMONSTRATED EPITHELIOID PHENOTYPIC
TRAITS IN XENOGRAFTS
In earlier in vitro studies, STAV-AB and STAV-FCS cells showed
robust phenotypic differences consistent with their respective
differentiation patterns (10). Characteristic ultrastructural fea-
tures of both xenografts were that of an epithelioid subtype of
malignant mesothelioma, as evidenced by desmosomes, numerous
slender, long microvilli on cell surfaces and in intracytoplasmic
neolumina, and absence of glycocalyx. Interestingly, the den-
sity of microvilli was lower in the STAV-FCS-derived xenografts
(Figure 6), indicating that the cells displayed a less differentiated
morphology.
FIGURE 5 | Microvessel density in xenografts demonstrated by
staining for reticulin fibers (Gordon and Sweets). Xenografts from
STAV-AB cells showed uniform vascularization, whereas xenografts from
STAV-FCS cells showed decreased vascularization at a depth of 0.5–1 mm
into the tumor. The tumor invasion front is seen at the top in both images.
XENOGRAFTS OF BOTH CELL SUB-LINES CONVERGED TOWARD A
SIMILAR GENOTYPE RESEMBLING THE ORIGINAL SARCOMATOID
CELLS
Chromosome 3 array CGH analysis was performed on the original
STAV-AB and STAV-FCS cell sub-lines and the derived xenografts.
Irrespective of their original cell sub-line, xenografts derived from
both cell sub-lines showed a similar pattern of chromosome 3
aberrations rather resembling the sarcomatoid STAV-FCS cells
(Figure 7; Table 2).
The original STAV-AB and STAV-FCS cell sub-lines shared a
common deletion at 3p14.3p21.3 (Figure 7; Table 2). Within this
region only six clones were lost in the xenografts. Copy num-
ber gains were seen in the sarcomatoid STAV-FCS cell sub-line
and in both xenografts. Three such shared regions with increased
copy number were seen predominantly on the 3q arm, comprising
the 3q21.2–3q22.1, and 3q26.2 regions. One clone (PR11-124n2)
showed copy number gain both in the STAV-FCS cell sub-line
and its xenograft, but was not present in the STAV-AB cells and
its derived xenograft, which makes it an FCS specific clone and a
possible candidate that might have role in epithelial-mesenchymal
transition. Interestingly, the 3p24.3 and 3q13.1 regions were found
to harbor copy number gains exclusively in the xenografts, whereas
they were not detected in the original cell sub-lines. The STAV-AB
xenograft showed elevated binding intensities in an area spanning
30 MB at 3q26.1–3q28. Some of the clones from this region (RP11-
24l16–RP11-79o17) were found in copy number gain also in the
STAV-FCS cell sub-line and its xenograft.
DISCUSSION
Mesothelioma cells are able to differentiate along the mesenchymal
to epithelial axis, and in biphasic tumors epithelioid and sarcoma-
toid cells are present side by side in the same tumor. Mesothelioma
differentiation is a critical factor influencing clinical outcome
and treatment response (11–13). Prognosis deteriorates dramat-
ically when the sarcomatous phenotype is dominant. However,
little is known about the factors regulating this differentiation
between phenotypes. The genetic background and microenviron-
mental clues underlying this process are also poorly understood,
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Table 2 | Regions of chromosome 3 and gene locations.
Chromosome band FISH clone Genes Gain/loss
STAV-AB
cell line
STAV-FCS
cell line
STAV-AB
xenograft
STAV-FCS
xenograft
3p24.3 RP11-255o19–
RP11-208g16
KAT2B, VENTXP7, RAB5A, KCNH8,
SATB1, PLCL2, RFTN1, GALNTL2, DPH3
Gain Gain
3p21.3–3p14 RP11-91p19–
RP11-169g24
LTF, TDGF1, WNT5a, RASSF1,
CACNA2D3, GNAI2, SEMA3B
Loss Loss Loss Loss
3q13.1 RP11-90i19 No genes Gain Gain
3q21.2–3q22.1 RP11-711f17,
PR11-124n2;
RP11-177o2–
RP11-893g19
ITGB5, SNX4, OSBPL11, ROPN1B,
ALD1HL1, KLF15, RAB7, MGLL,
RUVBL1, H1X, H1FOO, MBD4, IFT122,
TRH
Gain Gain Gain
3q26.2–3q28 RP11-24l16–
RP11-79o17
EVI1, TP63, LPP Gain Gain Gain
Table 3 | Volume density of blood vessels in xenografts.
Distance from tumor
margin (mm)
Mean density±SE
STAV-AB STAV-FCS
0–1.2 0.083±0.019 0.096±0.020
1.2–4 0.028±0.007 0.020±0.006
Table 4 | Microvessel density in xenografts (vessels/mm2).
Distance from tumor
margin (mm)
Mean density±SE
STAV-AB STAV-FCS
0–1.2 14.3±1.7 16.0±1.8
1.2–4 6.8±0.8 3.2±0.5
and relevant animal models addressing phenotypic changes and
molecular switches associated with this process are sparse. In
this study we describe the establishment of a xenograft model to
study malignant mesothelioma and we propose genes potentially
involved in epithelial or mesenchymal differentiation.
In cell culture, the two cell sub-lines used in this study have sta-
ble phenotypes with epithelioid and sarcomatoid growth patterns,
distinct immunophenotypes, and molecular signatures (14), reca-
pitulating in vitro the major morphological features of malignant
mesothelioma. In the present study, we demonstrate tumor cell
heterogeneity within each original cell sub-line, with the largest
non-dominant subpopulation found in the STAV-FCS cells. Chro-
mosome 3 CGH arrays indicated different dominating patterns
for the two sub-lines with a common deleted region at 3p14–21.3.
This deletion was the only change in the epithelioid cells, while the
sarcomatoid cells showed five additional amplified regions on 3q
(Figure 7; Table 2).
FIGURE 6 | Ultrastructural characterization of xenografts. Electron
microscopy revealed the presence of microvilli-laden neolumina in
xenografts from both phenotypes. A greater density of microvilli was
consistently found in the STAV-AB-derived xenografts. The density of
microvilli was strikingly lower in the STAV-FCS-derived xenografts,
suggesting that the cells displayed a less differentiated state. Scale bars are
2µm.
Following inoculation in SCID mice, both phenotypes were
able to initiate tumor growth. However, the tumor take was
initially low, and similarly to the clinical course of mesothelioma
a long latency period was required before tumor formation could
be seen. Serial passages resulted in a high take rate and faster
tumor formation. The low initial take rate is comparable to that
seen in other studies of mesothelioma xenografts (36), and sug-
gests clonal expansion from a precursor subpopulation, originally
being present as minor proportions in the inoculated cell sub-
lines, as supported by findings of heterogeneity using FISH. The
original heterogeneity seen by cytogenetics was maintained in
the xenografts, as evidenced by an increased proportion of het-
erogeneous subpopulation in the STAV-FCS-derived xenografts
compared to the STAV-AB-derived ones.
Xenografts derived from the two cell sub-lines converged to a
similar morphology with predominantly epithelioid characteris-
tics, as evidenced by both light and electron microscopy. Immuno-
histochemical analysis of differentiation markers confirmed this
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FIGURE 7 | Array comparative genomic hybridization analysis showing
gains and losses on chromosome 3 in cell lines and xenografts. Regions
indicative of gain are highlighted in red, whereas regions indicative of loss are
highlighted in green. Xenografts from both cell sub-lines showed a similar
pattern of gains and losses, except for a large terminal region on the q arm
gained in STAV-AB-derived xenografts. Compared to the cell sub-lines,
xenografts irrespective of origin were more similar to STAV-FCS cells,
suggesting a clonal expansion in the STAV-AB-derived xenografts of cells with
genetic similarities to STAV-FCS cells. The variability was greater in
xenografts, likely because those specimens were fixed in formaldehyde.
similarity between the two xenografts, with broadly similar expres-
sion levels of all investigated differentiation markers. Markers
for both epithelial and mesenchymal differentiation were found
to be positive, suggesting an intermediate phenotype although
the morphological characteristics resembled polygonal epithelioid
differentiation.
The convergent phenotypes observed in xenografts may be
explained by clonal expansion under a selection pressure in the
SCID mouse microenvironment, favoring cells with the most
prevalent sarcomatoid STAV-FCS chromosome 3 genotype, and
harboring common amplified regions on 3q. Although the mor-
phologic phenotype of the expanding cell clones were quite similar,
their respective growth rates differed considerably. Cells from the
sarcomatoid cell sub-line formed a 1 cm3 nodule much faster than
the epithelioid cells, also in the second generation of xenograft.
However, the total proliferation rate, measured in the harvested
xenograft as proportion of MIB-1 reactive cells, was lower in the
faster growing xenograft derived from sarcomatoid cells. To further
investigate this contradictory result, we analyzed microvessel den-
sity. While the sarcomatoid cell-derived xenograft had a slightly
higher density at the infiltration front compared to the corre-
sponding epithelioid cell xenograft, the corresponding density in
the deeper parts in the sarcomatoid cell-derived xenograft was
much lower with an obvious tendency to necrosis in the tissue.
Thus, an insufficient vascularization of the sarcomatoid xenograft,
in relation to its growth rate, is a possible explanation for the
discrepancy between macroscopic growth and MIB-1 expression.
Cytogenetic analysis of chromosome 3 showed that xenografts
derived from both cell lines had similar genotypes, most closely
resembling the more aggressive sarcomatoid cell sub-line. FISH
of chromosome 3 demonstrated genetically heterogeneous cell
populations in all cell lines and xenografts. We propose that this
heterogeneity may result in plasticity in differentiation patterns.
Different microenvironmental pressures may then cause prefer-
ential expansion of certain subpopulations. Certain genotypic
changes, manifested in this study as chromosome 3 rearrange-
ments, might be characteristics of the mesenchymal phenotype
(e.g., the clone RP11-124n2 at 3q21) or others of a more aggres-
sive sarcomatoid component of malignant mesotheliomas (clones
amplified in STAV-FCS and both xenografts). We can, however,
not rule out contributions to this process from epigenetic changes
induced by the microenvironment nor from de novo mutations.
The four different aCGH patterns have one region suggestive
of a deletion on 3p in common. This may represent an early aber-
ration necessary for the malignant phenotype and for the ability
of cells to survive in culture. The region located between 3p21.3
and 3p14.3, deleted in both cell sub-lines, contains several estab-
lished tumor suppressor genes including LTF, TDGF1, WNT5a,
and RASSF (37), as well as candidate tumor suppressors such as
CACNA2D3, GNAI2, and SEMA3B. The telomeric breakpoint of
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this region coincides with a previously described tumor break-
point region with instability characteristics (38). Breaks at this
region, containing special DNA structures with large segmental
duplications conferring chromosomes special features of instabil-
ity,observed in certain tumors, suggest a more aggressive genotype.
Rearrangement at this region was shown to be characteristic for
tumors with high plasticity/rearrangement rate and more aggres-
sive genotype (29). These findings fit the known natural history
of sarcomatoid vs epitheloid phenotypes of malignant mesothe-
lioma. Some clones within this region were also lost in the
xenografts as a hallmark of their clonal outgrowth, presumably
due to selective pressure in the SCID mouse microenvironment.
These two deleted regions at 3p21.3 in all cell lines and xenografts
are consistent with characteristic genetic changes in malignant
mesothelioma (39–41).
There were three common regions suggestive of increased copy
number in sarcomatoid cells and both xenografts, in which some
genes are of particular interest. The 3q21.3 region contains sev-
eral putative and reported oncogenes/tumor promoting genes.
Genes present in this region have functions in DNA-binding and
transcription.
A region at 3q26.1 suggestive of common amplification har-
bors genes with functions in DNA-binding, transcription, and
oncogenic transformation (see Table 2). This region contains
the EVI1 oncogene, which among other functions can destabi-
lize chromosomal organization (42). Another region at 3q26.1
does not contain any gene but has small miRNAs. Regions
between RP11-178k17 and RP11-54l9 contain the TP63 gene
at 190 Mb, which is a tumor promoting gene even though it
belongs to the p53 family. P63 acts primarily through negative
regulation by theDeltaNp63/p73 isoforms to regulate cell death
and differentiation (43).
The long incubation times needed to obtain tumor takes sug-
gest that the acquired xenografts represent clonal outgrowths from
cells representing a fraction of the original cell sub-lines. The
phenotypic similarity of cells originally derived from dissimilar
differentiation states demonstrates the importance of evolutionary
selection pressures in the mouse microenvironment. The chro-
mosomal rearrangements studied were also more similar between
xenografts than between the two original cell cultures. The cells
from which the xenografts originates may therefore represent a
stem cell-like subpopulation of tumor cells, more closely related
to each other than to the dominating cell subpopulations.
Major phenotypic differences were not seen between
xenografts, but the sarcomatoid mesothelioma cells had a faster
growth in vivo which mirrors the more aggressive biological behav-
ior of this tumor. The different growth patterns in mixed type
mesotheliomas could be a result of clonal outgrowth, which in
turn depends on the microenvironment in the tumor. The present
in vitro and corresponding in vivo model of malignant mesothe-
lioma is well characterized and can be used for studying the
interplay of environmental factors and the clonal evolution of a
heterogeneous tumor population.
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